주요우울증환자에서 세로토닌 6(5-HT6) 수용체 C267T 다형성과 Citalopram 치료반응에 대한 연구No Association between the 5-HT6 Receptor C267T Polymorphism and Response to Citalopram Treatment in Patient with Major Depressive Disorder
- Other Titles
- No Association between the 5-HT6 Receptor C267T Polymorphism and Response to Citalopram Treatment in Patient with Major Depressive Disorder
- Authors
- 한상우; 임세원; 오강섭; 강이헌; 이민수
- Issue Date
- Nov-2007
- Publisher
- 대한생물정신의학회
- Keywords
- Major depressive disorder; 5-HT6 receptor; C267T polymorphism; Citalopram
- Citation
- 생물정신의학, v.14, no.4, pp 262 - 267
- Pages
- 6
- Indexed
- KCI
- Journal Title
- 생물정신의학
- Volume
- 14
- Number
- 4
- Start Page
- 262
- End Page
- 267
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35827
- ISSN
- 1225-8709
2005-7571
- Abstract
- The serotonin 6 (5-HT6) receptor gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the C267T polymorphism in the 5-HT6 receptor gene and the treatment response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 8 weeks to the 90 patients who completed study. We found that the genotype, allele, and allele-carrier distributions did not differ significantly between MDD patients and normal controls. A main effect of an interaction of genotype with time on the decrease in the HAMD-21 score during the 8 weeks study period was not found. ANOVA revealed no significant effects of the C825T polymorphism on the decrease in the HAMD-21 score at each time period.These results suggest that the C267T polymorphism in the 5-HT6 receptor gene is not associated with citalopram treatment response. Key WordsMajor depressive disorder, 5-HT6 receptor , C267T polymorphism, citalopram.
- Files in This Item
-
Go to Link
- Appears in
Collections - 2. Clinical Science > Department of Psychiatry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.